We infer that immune checkpoint inhibitors of PD-L1 will constitute a novel and efficacious therapeutic strategy for aggressive DLBCL, and anticipate favourable outcomes similar to those observed in the management of certain solid malignancies [40, 41, 75–77]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.